The move signals a shift from the startup's original strategy of creating a cryptocurrency to compensate donors of genomic and clinical data.
The company also entered into a sales agreement with Cowen and Company to offer up to $75 million of its common stock for sale.
As previously disclosed, Bio-Rad's accounting firm needs more time to complete its audit and the company plans to file the form as soon as possible.
WUSTL bioinformatics spinout PierianDx disclosed in an SEC filing that it has raised slightly more than $3 million of a $5 million offering.
The New York Stock Exchange gave Alere an additional six months to file its 2016 annual report, but it also said it could commence delisting proceedings at any time.
The company borrowed $205 million in revolving loans from the credit facility, which matures on December 23, 2021.
The gene editing company has notified the SEC it plans to trade on the Nasdaq beginning in 2016 under the ticker “EDIT.”
The firm is selling stock and warrants to purchase stock to raise money for general corporate purposes and working capital.
Helicos said it will require "significant additional capital" before the end of the year to fund its operations. The company's "current financial resources raise substantial doubt about its ability to continue as a going concern."
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.